NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free GANX Stock Alerts $3.77 +0.04 (+1.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.68▼$3.9550-Day Range$3.27▼$5.0452-Week Range$2.00▼$6.19Volume102,211 shsAverage Volume152,390 shsMarket Capitalization$61.15 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Gain Therapeutics alerts: Email Address Gain Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside121.0% Upside$8.33 Price TargetShort InterestHealthy0.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.18) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector600th out of 938 stocksPharmaceutical Preparations Industry284th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingGain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, Gain Therapeutics has a forecasted upside of 121.0% from its current price of $3.77.Amount of Analyst CoverageGain Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.88% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently increased by 16.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GANX. Previous Next 2.6 News and Social Media Coverage News SentimentGain Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Gain Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for GANX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.00% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.97% of the stock of Gain Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gain Therapeutics are expected to grow in the coming year, from ($1.18) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Gain Therapeutics Stock (NASDAQ:GANX)Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Read More GANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GANX Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comGain Therapeutics (NASDAQ:GANX) Given Buy Rating at Chardan CapitalMarch 28, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 27, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 26, 2024 | globenewswire.comGain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 26, 2024 | americanbankingnews.comGain Therapeutics (NASDAQ:GANX) Shares Down 10.1% March 15, 2024 | globenewswire.comGain Therapeutics to Present at Public Ventures Discovery DayMarch 5, 2024 | msn.comEXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's DiseaseMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 5, 2024 | finance.yahoo.comGain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseFebruary 27, 2024 | finance.yahoo.comGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseFebruary 27, 2024 | globenewswire.comGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's DiseaseFebruary 23, 2024 | benzinga.comGain Therapeutics Stock (NASDAQ:GANX), Short Interest ReportFebruary 17, 2024 | finance.yahoo.comGANX Mar 2024 7.500 callFebruary 16, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst InsightFebruary 14, 2024 | finance.yahoo.comGain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightFebruary 14, 2024 | globenewswire.comGain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst InsightFebruary 7, 2024 | markets.businessinsider.comBuy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson’s Candidate GT-02287February 6, 2024 | marketwatch.comAmgen 4Q Revenue Surges as Acquisition Boosts ResultsFebruary 6, 2024 | finance.yahoo.comGain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseFebruary 6, 2024 | finance.yahoo.comUPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Gain Therapeutics’ Promising GT-02287 Advances Towards Key Clinical Milestones in Parkinson’s Disease TreatmentFebruary 1, 2024 | seekingalpha.comAmgen: Debt-Funded Buybacks Constrains Future Gains Per ShareJanuary 31, 2024 | finance.yahoo.comGain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational UpdateJanuary 24, 2024 | finance.yahoo.comGain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should KnowJanuary 17, 2024 | seekingalpha.comGANX Gain Therapeutics, Inc.January 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Gain Therapeutics’ GT-02287 Shows Promise in Parkinson’s Disease PipelineSee More Headlines Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/29/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GANX CUSIPN/A CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+121.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,590,000.00 Net MarginsN/A Pretax Margin-40,138.18% Return on Equity-199.03% Return on Assets-124.44% Debt Debt-to-Equity Ratio0.06 Current Ratio2.30 Quick Ratio2.30 Sales & Book Value Annual Sales$50,000.00 Price / Sales973.41 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book2.37Miscellaneous Outstanding Shares12,910,000Free Float11,490,000Market Cap$48.67 million OptionableOptionable Beta0.47 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Khalid Islam Ph.D. (Age 69)Founder & Chairman Comp: $75kMr. Matthias Alder LIC. IUR. (Age 59)LL.M., President, CEO & Director Comp: $593kKey CompetitorsDaré BioscienceNASDAQ:DARECheckpoint TherapeuticsNASDAQ:CKPTOcuphire PharmaNASDAQ:OCUPRockwell MedicalNASDAQ:RMTIEyenoviaNASDAQ:EYENView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 18,105 shares on 3/11/2024Ownership: 0.685%Vanguard Group Inc.Bought 18,105 shares on 2/15/2024Ownership: 0.685%Citadel Advisors LLCBought 2,900 shares on 2/15/2024Ownership: 0.000%Royal Bank of CanadaSold 9,752 shares on 2/14/2024Ownership: 1.551%Northern Trust CorpBought 30,236 shares on 2/13/2024Ownership: 0.337%View All Insider TransactionsView All Institutional Transactions GANX Stock Analysis - Frequently Asked Questions Should I buy or sell Gain Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GANX shares. View GANX analyst ratings or view top-rated stocks. What is Gain Therapeutics' stock price target for 2024? 3 brokerages have issued twelve-month price targets for Gain Therapeutics' stock. Their GANX share price targets range from $6.00 to $10.00. On average, they predict the company's share price to reach $8.33 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price. View analysts price targets for GANX or view top-rated stocks among Wall Street analysts. How have GANX shares performed in 2024? Gain Therapeutics' stock was trading at $3.27 at the beginning of 2024. Since then, GANX shares have increased by 15.3% and is now trading at $3.77. View the best growth stocks for 2024 here. Are investors shorting Gain Therapeutics? Gain Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 156,700 shares, an increase of 16.4% from the February 29th total of 134,600 shares. Based on an average daily trading volume, of 171,900 shares, the short-interest ratio is presently 0.9 days. Currently, 0.9% of the company's stock are sold short. View Gain Therapeutics' Short Interest. When is Gain Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our GANX earnings forecast. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.03. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.04 million. When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an initial public offering (IPO) on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Gain Therapeutics' major shareholders? Gain Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Royal Bank of Canada (1.55%), Vanguard Group Inc. (0.68%), Vanguard Group Inc. (0.68%), Northern Trust Corp (0.34%), Raymond James & Associates (0.18%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Eric I Richman and Matthias Alder. View institutional ownership trends. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GANX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.